ClinicalTrials.gg

Program

fropenem

Also written as “Faropenem”, “Faropenem(high dose group)” and “Faropenem(low-dose group)”.

Its studies are mostly in Community-Acquired Pneumonia, led by 2 companies.

Furthest: phase 4, since Sep 4, 20133 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical20 open or runningphase 3since Sep 4, 2013Jun 14, 2013none ahead
Dr. Md. Alimur Reza10 open or runningphase 4since Jan 26, 2025Jan 26, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 14, 2013First study: phase 2 study in Community-Acquired PneumoniaNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT01886053 · 189 enrolled · China
  2. Sep 4, 2013Phase 3 study in Community-Acquired PneumoniaSino Biopharmaceutical · NCT01937832 · 540 enrolled · China
  3. Jan 26, 2025Dr. Md. Alimur Reza's first study: phase 4 study in Community-Acquired PneumoniaNew to Dr. Md. Alimur RezaDr. Md. Alimur Reza · NCT06804096 · 129 enrolled · Bangladesh

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial penicillin-binding protein inhibitor”ChEMBL 37, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06804096Community-Acquired Pneumonia · Bangladesh4CompletedDr. Md. Alimur RezaJan 12, 2026129
NCT01937832Community-Acquired Pneumonia · China3UNKNOWNSino BiopharmaceuticalOct 2015540
NCT01886053Community-Acquired Pneumonia · China2CompletedSino BiopharmaceuticalJul 2012189

How it is read

Names in the registry

  • “Faropenem”, 2 entries
  • “Faropenem(high dose group)”, 1 entry
  • “Faropenem(low-dose group)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.